ABO blood group was analyzed in 70 patients with hydatidiform mole and 53 patients with malignant trophoblastic disease. 319 healthy pregnant women served as controls. The distribution of ABO blood groups in patients with hydatidiform mole did not deviate significantly from the distribution in the controls. There was a slight excess in group AB and a slight deficiency in group·in patients with hydatidiform mole. However, there was a significant decrease in blood group A and a slight excess in groups O, B and AB in patients with malignant trophoblastic disease compared with the distribution in healthy pregnant women. A higher mortality rate was observed in group B in patients with malignant trophoblastic disease. In conclusion, ABO blood group of patients with malignant trophoblastic disease can be an important prognostic factor in the diagnosis and treatment of the trophoblastic disease, if a large number of cases are compiled by many investigators.

Keywords:
ABO blood group, Hydatidiform mole, Malignant trophoblastic disease
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.